Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

May 31st 2020

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma

May 29th 2020

Savolitinib showed encouraging efficacy data and an improved safety profile versus sunitinib as a treatment for patients with MET-driven papillary renal cell carcinoma.

Tivozanib Showcases Superiority in Relapsed/Refractory RCC

May 29th 2020

Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.

Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC

May 29th 2020

Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.

Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma

May 29th 2020

Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.

Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma

May 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.

Expert Explains Effect of Age and Gender on Outcomes in RCC

May 21st 2020

Rana R. McKay, MD, sheds light on the impact of age and gender on the outcomes of patients with RCC, the implications of clinical determinants on toxicity, and where future research efforts will focus.

Expert Explains Effect of Age and Gender on Outcomes in RCC

May 21st 2020

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Tivozanib's Safety Profile Linked With Advantage in Advanced RCC Treatment

May 20th 2020

Brian I. Rini, MD, speaks about the TIVO-3 trial and how its results could provide patients with another “weapon in this disease.”

Dr. Subbiah on the Utility of Tivozanib in RCC

May 20th 2020

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Low-Intensity Surveillance Demonstrates Utility in NMIBC

May 20th 2020

Low-intensity surveillance may be comparable to high-intensity surveillance for cancer control in patients with high-risk non-muscle invasive bladder cancer.

Low-Intensity Surveillance Demonstrates Utility in NMIBC

May 19th 2020

Patients who had low-intensity cystoscopy surveillance underwent fewer transurethral resections but did not experience an increased risk of progression or bladder cancer death compared with those who had high-intensity surveillance.

Dr. Tsao on Improving Outcomes in RCC

May 16th 2020

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Dr. Tsao on Improving Outcomes in RCC

May 15th 2020

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Dr. Iyer on TRAEs With Erdafitinib in Urothelial Cancer

May 14th 2020

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

May 13th 2020

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

May 12th 2020

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Choueiri Spotlights Activity With Novel HIF-2a Inhibitor in Heavily Pretreated RCC

May 12th 2020

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.

Choueiri Spotlights Activity With Novel HIF-2α Inhibitor in Heavily Pretreated RCC

May 12th 2020

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.